Publication | Closed Access
The design of donecopride, a dual 5-HT4R agonist/AChE inhibitor with potential interest for AD treatment
39
Citations
0
References
2014
Year
Antiparasitic AgentPharmacotherapyAntimicrobial ChemotherapyQuinoline 21Chemical BiologyVisceral LeishmaniasisPharmaceutical ChemistryVitro Antileishmanial MoleculeMolecular PharmacologyMedicinal ChemistryNitroquinoline ScaffoldAntimicrobial Drug DiscoveryBiochemistryParasitic ProtozoaPharmacological AgentNeuropharmacologyPharmacologyPotential InterestAd TreatmentFunctional SelectivityNatural SciencesMedicineSmall MoleculesDrug Discovery
A series of nitrated 2-substituted-quinolines was synthesized and evaluated in vitro toward Leishmania donovani promastigotes. In parallel, the in vitro cytotoxicity of these molecules was assessed on the murine J774 and human HepG2 cell lines. Thus, a very promising antileishmanial hit molecule was identified (compound 21), displaying an IC50 value of 6.6 μM and CC50 values ≥ 100 μM, conferring quite good selectivity index to this molecule, in comparison with 3 drug-compounds of reference (amphotericin B, miltefosine and pentamidine). Compound 21 also appears as an efficient in vitro antileishmanial molecule against both Leishmania infantum promastigotes and the intracellular L. donovani amastigotes (respective IC50 = 7.6 and 6.5 μM). Moreover, hit quinoline 21 does not show neither significant antiplasmodial nor antitoxoplasmic in vitro activity and though, presents a selective antileishmanial activity. Finally, a structure–activity relationships study enabled to define precisely the antileishmanial pharmacophore based on this nitroquinoline scaffold: 2-hydroxy-8-nitroquinoline.